资源有限地区1型糖尿病干预集群的系统综述与经济评价
BACKGROUND: Over 9 million people are living with type 1 diabetes globally, with a disproportionate burden in resource-limited settings where access to care remains constrained.…
要点
- 移动健康干预在低收入国家具成本效益,每QALY花费1788国际美元。
- 干预集群(整合式照护、公私合作、技术增强自我管理)健康影响优于单一干预。
- 干预集群超出低收入国家WHO阈值,但在中高收入和高收入国家仍具成本效益。
核心结论
- 移动健康干预在具备支持性基础设施的收入环境中具成本效益。
- 干预集群健康影响更大但需更高投资,支持兼顾成本效益与本地实施能力的资源分配。
研究设计与样本
- 通过15名国际专家德尔菲过程验证三个干预集群,并构建微观模拟模型预测10年结局与成本。
临床怎么用
- 在具备基础设施的资源有限地区可优先考虑移动健康干预。
- 干预集群需更高投资,资源分配应兼顾成本效益与本地实施能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 9 million people are living with type 1 diabetes globally, with a disproportionate burden in resource-limited settings where access to care remains constrained. Individual interventions have shown modest benefits, but coordinated intervention clusters could achieve greater health impact. We aimed to evaluate the cost-effectiveness of intervention clusters for type 1 diabetes management in resource-limited settings. METHODS: We conducted a systematic review (PRISMA 2020) searching PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, Global Health Database, and WHO Global Health Library from Jan 1, 2000 to Aug 31, 2024, for type 1 diabetes interventions. We identified 89 studies evaluating four categories of individual interventions: diabetes self-management education and support, glucose monitoring technologies, task shifting to trained non-physician providers, and mobile health technologies. Through a Delphi process with 15 international experts, we validated three intervention clusters: integrated care delivery models, technology-enhanced self management, and public-private partnership models. We developed a microsimulation model to: project 10-year outcomes; 10 year outcomes from the point of intervention initiation in HbA1c, severe hypoglycaemia incidence, diabetic ketoacidosis incidence, microvascular and macrovascular complications, and health-related quality of life; and costs using WHO CHOICE methodology. Costs are expressed as percentage of gross domestic product per capita for cross-country comparability. The study is registered with PROSPERO (CRD420251066740). FINDINGS: We identified 89 studies (20 734 participants). Individual interventions achieved HbA1c reductions of 0·32-0·89% (3·5-9·7 mmol/mol). Mobile health showed favourable cost-effectiveness at INT$1788 (95% CI 1342-2456) per quality-adjusted life-year (QALY), representing 7·2% (5·4-9·8) of gross domestic product per capita in low-income countries. Intervention clusters achieved greater health impact than individual interventions: integrated care delivery generated 264·6 QALYs (198·5-330·7) per 1000 patients ($60 023 [45 018-78 029] per QALY); public-private partnership generate 281·5 QALYs (211·1-351·9; $60 624 [47 291-77 956] per QALY); and technology-enhanced self management generate 238·5 QALYs (178·9-298·1; $158 360 [123 456-201 234] per QALY). Clusters exceeded WHO thresholds for low-income settings but remained cost-effective for upper-middle and high-income countries, per World Bank classifications. INTERPRETATION: Mobile health interventions show cost-effectiveness across income settings where supporting infrastructure exists. Intervention clusters provide greater health impact but require higher investment. These findings support evidence-based resource allocation considering both cost-effectiveness and local implementation capacity. FUNDING: Breakthrough T1D.
引用
- Basu S, Zafra-Tanaka JH, Beran D, et al. Type 1 diabetes intervention clusters in resource-limited settings: a systematic review and economic evaluation. Lancet Diabetes Endocrinol. 2026. PMID: 42140211. doi:10.1016/S2213-8587(26)00002-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。